GlassScriptPhysician profile
Ashley Rojas
NPI 1316750995
$6,875.82
in general payments reported to CMS, 2019-2025
25 companies · $6,876 in 2025
The $6,876 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $6,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,776 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,775.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $801.75 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $780.55 | 2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $699.44 | 2025 | Zoryve |
| Genzyme Corporation | $512.12 | 2025 | |
| Ucb, INC. | $501.02 | 2025 | Bimzelx |
| Incyte Corporation | $463.79 | 2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $423.57 | 2025 | Anzupgo, Adbry, Spevigo |
| Novartis Pharmaceuticals Corporation | $301.69 | 2025 | |
| Revance Therapeutics, INC. | $269.32 | 2025 | Daxxify, Daxi |
| Lilly USA, LLC | $239.96 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $229.88 | 2025 | Nemluvio |
| Abbvie INC. | $215.07 | 2025 | |
| Pfizer INC. | $180.03 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $172.53 | 2025 | Cabtreo |
| Boston Scientific Corporation | $162.92 | 2025 | Watchman, Enroute Transcarotid Neuroprotection System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $154.50 | 2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.52 | 2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $136.71 | 2025 | Tremfya |
| Almirall LLC | $119.59 | 2025 | Seysara, Klisyri |
| Sun Pharmaceutical Industries INC. | $101.75 | 2025 | |
| Lnhc, INC | $96.96 | 2025 | Zelsuvmi |
| Organon LLC | $57.45 | 2025 | Vtama |
| Journey Medical Corporation | $50.84 | 2025 | |
| Botanix Sb INC | $29.01 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $23.85 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.